======= STT3B =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: STT3B
  * **<color #00a2e8>Official Name</color>**: STT3 oligosaccharyltransferase complex catalytic subunit B
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=201595|201595]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q8TCJ2|Q8TCJ2]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=STT3B&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20STT3B|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/608605|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  The protein encoded by this gene is a catalytic subunit of a protein complex that transfers oligosaccharides onto asparagine residues. Defects in this gene are a cause of congenital disorder of glycosylation Ix (CDG1X). [provided by RefSeq, Jun 2014]. 
  * **<color #00a2e8>UniProt Summary</color>**:  Catalytic subunit of the N-oligosaccharyl transferase (OST) complex which catalyzes the transfer of a high mannose oligosaccharide from a lipid-linked oligosaccharide donor to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains. N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). STT3B is present in a small subset of OST complexes and mediates both cotranslational and post-translational N-glycosylation of target proteins: STT3B-containing complexes are required for efficient post-translational glycosylation and while they are less competent than STT3A-containing complexes for cotranslational glycosylation, they have the ability to mediate glycosylation of some nascent sites that are not accessible for STT3A. STT3B-containing complexes also act post-translationally and mediate modification of skipped glycosylation sites in unfolded proteins. Plays a role in ER-associated degradation (ERAD) pathway that mediates ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins by mediating N-glycosylation of unfolded proteins, which are then recognized by the ERAD pathway and targeted for degradation. Mediates glycosylation of the disease variant AMYL- TTR 'Asp-38' of TTR at 'Asn-118', leading to its degradation. {ECO:0000269|PubMed:19167329, ECO:0000269|PubMed:22607976, ECO:0000305}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|STT3|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|oligosaccharyltransferase I complex|
|co-translational protein modification|
|dolichyl-diphosphooligosaccharide-protein glycotransferase activity|
|oligosaccharyltransferase complex|
|glycoprotein catabolic process|
|protein N-linked glycosylation via asparagine|
|peptidyl-asparagine modification|
|ubiquitin-dependent ERAD pathway|
|protein N-linked glycosylation|
|ERAD pathway|
|response to unfolded protein|
|response to topologically incorrect protein|
|carbohydrate derivative catabolic process|
|response to endoplasmic reticulum stress|
|protein glycosylation|
|macromolecule glycosylation|
|glycosylation|
|glycoprotein biosynthetic process|
|proteasome-mediated ubiquitin-dependent protein catabolic process|
|proteasomal protein catabolic process|
|post-translational protein modification|
|glycoprotein metabolic process|
|ubiquitin-dependent protein catabolic process|
|modification-dependent protein catabolic process|
|modification-dependent macromolecule catabolic process|
|proteolysis involved in cellular protein catabolic process|
|protein-containing complex|
|carbohydrate derivative biosynthetic process|
|cellular protein catabolic process|
|protein catabolic process|
|peptidyl-amino acid modification|
|cellular macromolecule catabolic process|
|response to organonitrogen compound|
|endoplasmic reticulum|
|carbohydrate derivative metabolic process|
|macromolecule catabolic process|
|organonitrogen compound catabolic process|
|response to nitrogen compound|
|proteolysis|
|organonitrogen compound biosynthetic process|
|cellular response to stress|
|cellular macromolecule biosynthetic process|
|macromolecule biosynthetic process|
|organic substance catabolic process|
|cellular catabolic process|
|membrane|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-2.31|
|[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|-1.87|
|[[:results:exp179|Combretastatin A4 0.002 to 0.003μM day4 R04 exp179]]|-1.84|
|[[:results:exp466|Cannabidiol 20μM R08 exp466]]|-1.77|
|[[:results:exp317|Geldanamycin 0.015 to 0.05μM on day4 R07 exp317]]|-1.72|
|[[:results:exp493|IL-3 9ng/ml R08 exp493]]|-1.71|
|[[:results:exp82|Torin1 0.08μM R02 exp82]]|1.76|
|[[:results:exp30|Rapamycin 10μM R00 exp30]]|1.87|
|[[:results:exp538|ZLN024 50μM R08 exp538]]|1.89|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|1.93|
|[[:results:exp455|Benzoate 10000μM R08 exp455]]|2.02|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|2.07|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|2.2|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|2.23|
|[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|2.74|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|2.95|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|3.22|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|3.8|
|[[:results:exp214|2-Deoxy-D-glucose 800μM R05 exp214]]|4.35|
|[[:results:exp418|Tunicamycin 0.04μM R07 exp418]]|5.69|
|[[:results:exp420|Tunicamycin 0.04 to 0.125μM  on day4 R07 exp420]]|6.62|
|[[:results:exp419|Tunicamycin 0.04 to 0.075μM  on day4 R07 exp419]]|6.72|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:m:magt1|MAGT1]]|0.651|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 6/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|1/28|
|bone|0/26|
|breast|1/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|2/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|1/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 14925
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 8.51 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='STT3B Expression in NALM6 Cells: 8.51'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>